Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages 1081-1093

  Sehn, Laurie H ^a,b   Chua, Neil ^c   Mayer, Jiri ^d   Dueck, Gregg ^a   Trněný, Marek ^e   Bouabdallah, Kamal ^f   Fowler, Nathan ^g   Delwail, Vincent ^h   Press, Oliver ⁱ   Salles, Gilles ^j   Gribben, John ^k   Lennard, Anne ^l   Lugtenburg, Pieternella J ^m   Dimier, Natalie ⁿ   Wassner Fritsch, Elisabeth ^o   Fingerle Rowson, Günter ^o   Cheson, Bruce D ^p  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g UNIVERSITY OF TEXAS   (United States)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ USA   (United States)

^j UNIVERSITÉ LYON 1   (France)

^k QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m ERASMUS MC CANCER INSTITUTE   (Netherlands)

ⁿ ROCHE PRODUCTS LTD   (United Kingdom)

^o F HOFFMANN LA ROCHE LTD   (Switzerland)

^p GEORGETOWN UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASIA; ASTHENIA; CENTRAL AMERICA; CHILL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG FATALITY; DYSPNEA; EUROPE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NORTH AMERICA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINUSITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; LYMPHOMA, NON-HODGKIN; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RITUXIMAB; SURVIVAL RATE;

EID: 84977537257     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30097-3     Document Type: Article

References (31)

1. 1 Liu, Q, Fayad, L, Cabanillas, F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24 (2006), 1582–1589.
2. 2 Fisher, RI, LeBlanc, M, Press, OW, Maloney, DCG, Unger, JM, Miller, TP, New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23 (2005), 8447–8452.
3. 3 Swenson, WT, Wooldridge, JE, Lynch, CF, Forman-Hoffman, VL, Chrischilles, E, Link, BK, Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23 (2005), 5019–5026.
4. 4 Tan, D, Horning, SJ, Hoppe, RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122 (2013), 981–987.
5. 5 Forstpointner, R, Dreyling, M, Repp, R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 (2004), 3064–3071.
6. 6 Hiddemann, W, Kneba, M, Dreyling, M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone—results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 106 (2005), 3725–3732.
7. 7 Marcus, R, Imrie, K, Solal-Celigny, P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisolone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 28 (2008), 4579–4586.
8. 8 Hochster, H, Weller, E, Gascoyne, RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 27 (2009), 1607–1614.
9. 9 van Oers, MH, Van Glabbeke, M, Giurgea, L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28 (2010), 2853–2858.
10. 10 Friedberg, JW, Cohen, P, Chen, L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26 (2008), 204–210.
11. 11 Kahl, BS, Bartlett, NL, Leonard, JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study. Cancer 116 (2010), 106–114.
12. 12 Cheson, BD, Wendtner, CM, Pieper, A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin's lymphomas and multiple myeloma. Clin Lymphoma Myeloma 10 (2010), 21–27.
13. 13 Herter, S, Herting, F, Mundigl, O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 12 (2013), 2031–2042.
14. 14 Mössner, E, Brünker, P, Moser, S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 115 (2010), 4393–4402.
15. 15 Salles, G, Morschhauser, F, Lamy, T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119 (2012), 5126–5132.
16. 16 Salles, G, Morschhauser, F, Solal-Céligny, P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin's lymphoma: results of the phase II GAUGUIN study. J Clin Oncol 31 (2013), 2920–2926.
17. 17 Sehn, LH, Assouline, SE, Stewart, DA, et al. A phase I study of obinutuzumab induction followed by two years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119 (2012), 5118–5125.
18. 18 Sehn, LH, Goy, A, Offner, FC, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 33 (2015), 3467–3474.
19. 19 Cheson, BD, Pfistner, B, Juweid, ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007), 579–586.
20. 20 Cephalon Incorporated. TREANDA (bendamustine hydrochloride injection, solution, concentrate) United States product information. http://www.treanda.com/pdf/TREANDA_final_PI.pdf, 2015 (accessed Dec 1, 2015).
21. 21 Astellas Pharma GmbH. LEVACT (bendamustine hydrochloride powder concentrate for solution for infusion) Summary of Product Characteristics. http://www.medicines.org.uk/EMC/medicine/23469/SPC/Levact+2.5+mg+ml+powder+for+concentrate+for+solution+for+infusion/, 2014 (accessed Dec 1, 2015).
22. 22 Rummel, MJ, Al Batran, S, Kim, SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low grade non Hodgkin's lymphoma. J Clin Oncol 23 (2005), 3383–3389.
23. 23 Robinson, KS, Williams, ME, van der Jagt, RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26 (2008), 4473–4479.
24. 24 Lee, L, Wang, L, Crump, M, Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol 22 (2011), 1392–1403.
25. 25 Pott, C, Belada, D, Danesi, N, et al. Analysis of minimal residual disease in follicular lymphoma patients in Gadolin, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. Blood, 126, 2015, 3978.
26. 26 Marcus, R, Imrie, K, Belch, A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005), 1417–1423.
27. 27 Cheson, BD, Wendtner, CM, Pieper, A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10 (2010), 21–27.
28. 28 Czuczman, MS, Fayad, L, Delwail, V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119 (2012), 3698–3704.
29. 29 Witzig, TE, Flinn, IW, Gordon, LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002), 3262–3269.
30. 30 Horning, SJ, Younes, A, Jain, V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23 (2005), 712–719.
31. 31 Gopal, AK, Kahl, BS, de Vos, S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370 (2014), 1008–1018.